E3 PreliminaryPreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression.
Maes, Michael, Mihaylova, Ivanka, Leunis, Jean-Claude · Neuro endocrinology letters · 2007
Quick Summary
This study found that people with ME/CFS and depression have higher levels of specific immune proteins (IgM antibodies) that attack a substance called phosphatidyl inositol in their blood compared to healthy people. These antibody levels were linked to fatigue and depression symptoms, suggesting that an abnormal immune response against this substance might contribute to both conditions.
Why It Matters
This research suggests ME/CFS and depression may share a common immune mechanism involving antibodies against a critical cell signaling molecule. If confirmed in larger studies, this finding could lead to specific biomarkers for diagnosis and potentially targeted immune-modulating treatments for both conditions.
Observed Findings
- Serum IgM antibody levels against phosphatidyl inositol were significantly higher in major depression and CFS patients compared to healthy controls and partial CFS patients.
- Positive correlations existed between serum IgM-Pi levels and fatigue symptoms on the FibroFatigue Scale.
- Positive correlations existed between serum IgM-Pi levels and depression symptoms on the FibroFatigue Scale.
- Partial CFS patients had IgM-Pi levels more similar to healthy controls than to full CFS patients.
Inferred Conclusions
- An IgM-mediated autoimmune response directed against phosphatidyl inositol may be a shared pathophysiological feature of both major depression and ME/CFS.
- Increased oxidative and nitrosative stress in both conditions may drive the development of these anti-Pi antibodies.
- These autoantibodies may impair intracellular signaling by disrupting production of phosphoinositide signaling molecules, contributing to core symptoms of fatigue and depression.
Remaining Questions
- What are the functional consequences of anti-Pi antibodies on intracellular signaling pathways, and do they directly cause symptom burden?
- Do anti-Pi antibody levels fluctuate with disease severity, remission, or treatment response over time?
What This Study Does Not Prove
This cross-sectional study establishes association only, not causation—elevated anti-Pi antibodies may be a consequence rather than a cause of ME/CFS and depression. The small sample sizes (14 per group) limit generalizability, and the study does not demonstrate that these antibodies directly cause the observed symptoms or functional impairment. No longitudinal data show whether antibody levels change with disease progression or treatment response.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- PMID
- 18063934
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →